NEW YORK, Sept. 24, 2015 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache, will present at the 15th Annual Biotech in Europe Forum for Global Partnering and Investment in Basel, Switzerland. Leland Gershell, M.D., Ph.D., Tonix’s chief financial officer, will deliver a corporate overview on Tuesday, September 29, 2015, at 12:15 p.m. CEST.
Dr. Gershell will also participate in a bio-pharma industry leader roundtable titled “Neuroscience & Pain II – PAIN” on September 29th at 4:40 p.m. CEST. The panel discussion will focus on the latest neuroscience research and development, therapeutic innovations, and advancements in promising product candidates for the treatment and management of pain.
The Annual Biotech in Europe Forum for Global Partnering and Investment brings together a cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. For more information, visit www.sachsforum.com.
About Tonix Pharmaceuticals Holding Corp.
Tonix is dedicated to the invention and development of novel pharmaceutical products for medical conditions that it believes have broad societal impact, that are not well served by currently available therapies and that represent large potential commercial opportunities. Tonix’s Tonmya™ is currently being evaluated in the Phase 3 AFFIRM study in fibromyalgia. TNX-102 SL, the same proprietary product candidate as Tonmya, is currently being evaluated in the Phase 2 AtEase study in post-traumatic stress disorder. A Phase 2 proof-of-concept study of TNX-201 in episodic tension-type headache is ongoing. This press release and further information about Tonix can be found at www.tonixpharma.com.
Tonmya™, TNX-102 SL and TNX-201 are Investigational New Drugs and have not been approved for any indications.
Safe Harbor / Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our possible need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2014 and Quarterly Report on Form 10-Q for the period ended June 30, 2015, as filed with the Securities and Exchange Commission (the “SEC”) on February 27, 2015 and August 7, 2015, respectively, and future periodic reports filed with the SEC on or after the date hereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.
CONTACT: Leland Gershell
Chief Financial Officer
(212) 980-9155 x104
[email protected]
Jenene Thomas Communications (investors)
Jenene Thomas
(908) 938-1475
[email protected]
Dian Griesel Int'l. (media)
Susan Forman / Laura Radocaj
(212) 825-3210
[email protected]
[email protected]